Single-Drug Regimen Now Advised for Uncomplicated Gonorrhea
TUESDAY, Jan. 5, 2021 -- A single 500-mg intramuscular dose of ceftriaxone is recommended for treatment of uncomplicated urogenital, anorectal, and pharyngeal gonorrhea, according to updated guidelines published in the Dec. 18 issue of the U.S.... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - January 5, 2021 Category: Pharmaceuticals Source Type: news
Notes from the Field: First Case in the United States of Neisseria gonorrhoeae Harboring Emerging Mosaic penA60 Allele, Conferring Reduced Susceptibility to Cefixime and Ceftriaxone
This report describes an instance of an antibiotic-resistant strain of gonorrhea occurring in Nevada. (Source: CDC Morbidity and Mortality Weekly Report)
Source: CDC Morbidity and Mortality Weekly Report - December 10, 2020 Category: American Health Tags: Gonorrhea and Drug Resistance MMWR Morbidity & Mortality Weekly Report Source Type: news
Glutamate transporter-1 link astrocytes with heightened aggressive behavior induced by steroid abuse in male CF1 mice - Rodolphi MS, Kopczynski A, Carteri RBK, Sartor M, Fontella FU, Feldmann M, Hansel G, Strogulski NR, Portela LV.
The astrocytic glutamate transporter GLT-1 performs glutamate uptake thereby mediating NMDAr responses in neurons. Ceftriaxone (CEF) upregulates astrocytic GLT-1 expression/activity, which could counteract excessive glutamate levels and aggressive behavior... (Source: SafetyLit)
Source: SafetyLit - October 27, 2020 Category: International Medicine & Public Health Tags: Alcohol and Other Drugs Source Type: news
Ceftriaxone dosing in patients admitted from the emergency department with sepsis
The objective of this study is to determine the ceftriaxone dose that achieves an unbound trough concentration>= 0.5 mg/L in> 90% of adult patients receiving once-daily dosing presenting to the emergency department (ED) with sepsis. Method(s): We performed a prospective single-centre pharmacokinetic study. A single unbound plasma ceftriaxone concentration was obtained from each patient using blood collected as part of routine clinical practice within the first dosing interval. Samples were analysed using a validated ultra-high pressure liquid chromatography method. Population pharmacokinetic analysis and Monte Carlo simula...
Source: Current Awareness Service for Health (CASH) - October 9, 2020 Category: Consumer Health News Source Type: news
Test accurately IDs people whose gonorrhea can be cured with simple oral antibiotic
A test designed by UCLA researchers can pinpoint which people with gonorrhea will respond successfully to the inexpensive oral antibiotic ciprofloxacin, which had previously been sidelined over concerns the bacterium that causes the infection was becoming resistant to it.In research published in the peer-reviewed journal Clinical Infectious Diseases,a UCLA-led team found thatof106 subjectsthe test identified as having a strain ofgonorrhea called wild-type gyrA serine, all were cured with a single dose of oral ciprofloxacin. Though the test has been available for three years, this is the first time it has been systematicall...
Source: UCLA Newsroom: Health Sciences - August 12, 2020 Category: Universities & Medical Training Source Type: news
Comparison of Ceftriaxone and Ampicillin/Sulbactam for CAP Comparison of Ceftriaxone and Ampicillin/Sulbactam for CAP
How do these antibiotics for treating non-aspiration community-acquired pneumonia compare? Is one more effective than the other?BMC Pulmonary Medicine (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - July 31, 2020 Category: Consumer Health News Tags: Pulmonary Medicine Journal Article Source Type: news
Update on Extensively Drug-Resistant Salmonella Serotype Typhi Infections Among Travelers to or from Pakistan and Report of Ceftriaxone-Resistant Salmonella Serotype Typhi Infections Among Travelers to Iraq --- United States, 2018--2019
New findings from CDC ' s enhanced surveillance system show that ceftriaxone-resistant Salmonella Typhi, the bacteria that causes typhoid fever, is a growing public health threat in Pakistan and Iraq. (Source: CDC Morbidity and Mortality Weekly Report)
Source: CDC Morbidity and Mortality Weekly Report - May 21, 2020 Category: American Health Tags: MMWR Morbidity & Mortality Weekly Report Salmonella Typhoid Fever Source Type: news
Prevalence ofAntibiotic-Resistant Pathogens in Culture-Proven Sepsis and Outcomes Associated With Inadequate and Broad-Spectrum Empiric Antibiotic Use
Conclusions and Relevance: In this study, most patients with community-onset sepsis did not have resistant pathogens, yet broad-spectrum antibiotics were frequently administered. Both inadequate and unnecessarily broad empiric antibiotics were associated with higher mortality. These findings underscore the need for better tests to rapidly identify patients with resistant pathogens and for more judicious use of broad-spectrum antibiotics for empiric sepsis treatment. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - May 6, 2020 Category: Consumer Health News Source Type: news
Antibiotic adverse events on an outpatient parenteral antibiotic service: a retrospective cohort study
Analysis of adverse event data from use of ceftriaxone, ertapenem, daptomycin, teicoplanin, piperacillin/tazobactam and meropenem on an outpatient parenteral antibiotic service shows piperacillin/tazobactam linked to the highest rate of toxicity compared to other antibiotics. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - February 27, 2020 Category: Consumer Health News Source Type: news
GlaxoSmithKline announces start of phase III trial of gepotidacin in treatment of uncomplicated urinary tract infection (UTI) and urogenital gonorrhoea
Gepotidacin is first in new chemical class of antibiotics called triazaacenaphthylene bacterial topoisomerase inhibitors. Development programme comprises two separate studies, EAGLE-1 (vs. ceftriaxone + azithromycin in gonorrhoea) and EAGLE-2 (vs. nitrofurantoin for UTI). (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - October 30, 2019 Category: Consumer Health News Source Type: news
Intravenous ceftriaxone at home versus intravenous flucloxacillin in hospital for children with cellulitis: a cost-effectiveness analysis
Australian study (n=180) found that the institutional cost per patient episode was lower with home ceftriaxone vs inpatient flucloxacillin (AUS$1965 vs $3775). As the QALY improvement was also greater with cetriaxone, cost-effectiveness analysis was redundant. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - September 4, 2019 Category: Consumer Health News Source Type: news
Suprax (cefixime) vs. Rocephin (ceftriaxone)
Title: Suprax (cefixime) vs. Rocephin (ceftriaxone)Category: MedicationsCreated: 7/18/2019 12:00:00 AMLast Editorial Review: 7/18/2019 12:00:00 AM (Source: MedicineNet Medications General)
Source: MedicineNet Medications General - July 18, 2019 Category: Drugs & Pharmacology Source Type: news
Intravenous flucloxacillin treatment is associated with a high incidence of hypokalaemia
Retrospective cohort study (n=161; mean age 70 years) found that hypokalaemia occurred significantly more often in patients receiving flucloxacillin vs ceftriaxone (42% vs 14%). Moreover, follow ‐up potassium levels were significantly lower during flucloxacillin therapy. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - June 27, 2019 Category: Consumer Health News Source Type: news
Lupin Pharmaceuticals, Inc. Issues Voluntary Recall of Ceftriaxone for Injection USP, 250mg, 500mg, 1g and 2g
Lupin Pharmaceuticals, Inc. is voluntarily recalling 5 lots of Ceftriaxone for Injection, USP, 250mg, 10 lots of Ceftriaxone for Injection, USP, 500mg, 24 lots of Ceftriaxone for Injection, USP, 1g and 3 lots of Ceftriaxone for Injection, USP 2g, to the hospital/physician level. (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - June 5, 2019 Category: Drugs & Pharmacology Authors: FDA Source Type: news
Amoxicillin vs. Ceftriaxone
Title: Amoxicillin vs. CeftriaxoneCategory: MedicationsCreated: 5/30/2019 12:00:00 AMLast Editorial Review: 5/30/2019 12:00:00 AM (Source: MedicineNet Medications General)
Source: MedicineNet Medications General - May 30, 2019 Category: Drugs & Pharmacology Source Type: news
